• Travere Therapeutics recently received U.S. FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only approved medicine for this rare kidney disease.
• This approval extends FILSPARI’s use beyond IgA nephropathy into a second rare kidney disease and opens access to an estimated more than 30,000 additional U.S. FSGS patients without nephrotic syndrome, backed by Phase 3 data showing greater proteinuria reductions versus irbesartan.
• We will now examine how FILSPARI’s first-in-class FSGS approval and expanded addressable population reshape Travere’s investment narrative and growth profile.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

Travere Therapeutics Investment Narrative Recap

To own Travere, you need to believe FILSPARI can anchor a focused rare kidney franchise while the company moves toward profitability on a narrow product base. The FSGS approval is a key near term catalyst because it broadens FILSPARI’s labeled use and patient pool, but it does not remove the core risk that Travere still leans heavily on a single drug in competitive, high-scrutiny markets.

The most relevant prior development was the FDA’s January decision to extend the FILSPARI FSGS review period to April 13, 2026, which set up this week’s approval as a binary event. With that delay now resolved in Travere’s favor, attention is likely to shift back to execution risks around REMS requirements, payer access, and sustaining FILSPARI uptake across both IgAN and FSGS.

Yet against this good news, investors should still recognize the ongoing risk that heavy dependence on FILSPARI in tightening pricing and regulatory conditions...

Travere Therapeutics' narrative projects $1.1 billion revenue and $289.1 million earnings by 2029.

Uncover how Travere Therapeutics' forecasts yield a $42.50 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could climb toward about US$1.5 billion and earnings to around US$576 million, but this new FSGS approval might either reinforce or challenge those expectations, especially if you worry about concentrated product risk and future pricing pressure.

Explore 8 other fair value estimates on Travere Therapeutics - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Travere Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.